Minerva Neuroscie (NERV) Stock Price, Quote & News

Company Profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neur...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 600 7373

Website: www.minervaneurosciences.com

Address:

1500 District Avenue, Burlington, United States

Stockstockerr Jun. 10 at 2:52 PM

$ALT looking good $DMN is the really money maker in the long run $RUN now that $NERV is on hold what will happen to this one?

0 · Reply

Stockstockerr Jun. 10 at 7:04 AM

$NERV $RGS 626% since this post 🤣

0 · Reply

StockHolder2025 Jun. 4 at 10:27 AM

$NERV time to fly 🚀🚀🚀

0 · Reply

ka1954 May. 22 at 8:23 PM

$NERV how long will this stock remain dead?

2 · Reply

FlicFlac May. 15 at 11:41 AM

$NERV no never proper communication from the company.. disappointing :(

0 · Reply

GrindTime May. 14 at 7:19 PM

$NERV oof?

0 · Reply

stocklion2 Apr. 16 at 6:11 AM

$NERV The company trading under the symbol $ NOVA has a net asset value of $2.7 billion, yet it’s currently sitting at a market cap of just $30 million. These shares are massively undervalued — grab them while they’re still cheap!

0 · Reply

PenkeTrading Apr. 16 at 4:47 AM

I found you a Bearish Engulfing Candle Pattern on the daily chart of Minerva Neurosciences Inc. $NERV #BearishEngulfingCandle #NASDAQ

0 · Reply

ka1954 Apr. 9 at 1:39 PM

$NERV stop selling u idiots !!! if nobody sells this can rally

0 · Reply

NVDAMillionaire Mar. 26 at 10:58 AM

$NERV FDA threw major curveball with CRL. Roluperidone needs more work but potential still looks promising. Watching closely for next steps in schizophrenia treatment development. Might add small position if they navigate regulatory hurdles effectively. standout article: https://beyondspx.com/article/minerva-neurosciences-navigating-challenges-in-cns-drug-development

0 · Reply

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates

Feb 25, 2025, 7:00 AM EST - 4 months ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates

Nov 5, 2024, 7:30 AM EST - 8 months ago

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates

May 1, 2024, 7:30 AM EDT - 1 year ago

Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates

Feb 27, 2024, 8:14 AM EST - 1 year ago

US FDA declines to approve Minerva Neurosciences' schizophrenia drug

Feb 22, 2024, 7:00 AM EST - 1 year ago

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

Nov 7, 2023, 7:30 AM EST - 1 year ago

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

Aug 23, 2023, 4:05 AM EDT - 2 years ago

Minerva Neurosciences: There's Probably Time For One More Rally

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

Jun 28, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

May 19, 2023, 5:34 PM EDT - 2 years ago

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

May 15, 2023, 11:26 AM EDT - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q1 2023 Earnings Call Transcript

May 15, 2023, 7:30 AM EDT - 2 years ago

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 10, 2023, 8:00 AM EDT - 2 years ago

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

May 8, 2023, 8:30 AM EDT - 2 years ago

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

Mar 8, 2023, 11:31 AM EST - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript

Mar 8, 2023, 7:30 AM EST - 2 years ago

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Mar 1, 2023, 8:30 AM EST - 2 years ago

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

Nov 9, 2022, 10:02 AM EST - 2 years ago

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Nov 9, 2022, 8:00 AM EST - 2 years ago

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Nov 2, 2022, 8:30 AM EDT - 2 years ago

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

Oct 17, 2022, 8:51 AM EDT - 2 years ago

Minerva Neurosciences to request meeting with FDA about schizophrenia drug

Oct 17, 2022, 8:30 AM EDT - 2 years ago

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Sep 9, 2022, 4:05 PM EDT - 3 years ago

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

Aug 22, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

May 4, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

Apr 7, 2022, 1:01 PM EDT - 3 years ago

Minerva Outlines Next Steps For US Application For Schizophrenia Candidate

Apr 7, 2022, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Mar 1, 2022, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

Feb 28, 2022, 8:30 AM EST - 3 years ago

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Nov 8, 2021, 2:11 PM EST - 3 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 3 years ago

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

Nov 3, 2021, 8:30 AM EDT - 3 years ago

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

Nov 1, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

Oct 11, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Promotion of Geoff Race to President

Sep 30, 2021, 10:32 AM EDT - 4 years ago

Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

Sep 30, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Aug 2, 2021, 12:19 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q2 2021 Results - Earnings Call Transcript

Aug 2, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

Jul 26, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

Jun 10, 2021, 8:30 AM EDT - 4 years ago

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

May 28, 2021, 8:00 AM EDT - 4 years ago

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

May 12, 2021, 4:40 PM EDT - 4 years ago

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

May 12, 2021, 7:30 AM EDT - 4 years ago

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 11, 2021, 4:15 PM EDT - 4 years ago

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 5, 2021, 5:10 PM EDT - 4 years ago

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

Mar 8, 2021, 12:35 PM EST - 4 years ago

Minerva Neurosciences, Inc.'s (NERV) CEO Remy Luthringer on Q4 2020 Results - Earnings Call Transcript

Mar 8, 2021, 7:30 AM EST - 4 years ago

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

Feb 8, 2021, 9:43 AM EST - 4 years ago

NERV DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Minerva Neurosciences, Inc. Investors to Secure Counsel Before Important Monday Deadline - NERV

Stockstockerr Jun. 10 at 2:52 PM

$ALT looking good $DMN is the really money maker in the long run $RUN now that $NERV is on hold what will happen to this one?

0 · Reply

Stockstockerr Jun. 10 at 7:04 AM

$NERV $RGS 626% since this post 🤣

0 · Reply

StockHolder2025 Jun. 4 at 10:27 AM

$NERV time to fly 🚀🚀🚀

0 · Reply

ka1954 May. 22 at 8:23 PM

$NERV how long will this stock remain dead?

2 · Reply

FlicFlac May. 15 at 11:41 AM

$NERV no never proper communication from the company.. disappointing :(

0 · Reply

GrindTime May. 14 at 7:19 PM

$NERV oof?

0 · Reply

stocklion2 Apr. 16 at 6:11 AM

0 · Reply

PenkeTrading Apr. 16 at 4:47 AM

I found you a Bearish Engulfing Candle Pattern on the daily chart of Minerva Neurosciences Inc. $NERV #BearishEngulfingCandle #NASDAQ

0 · Reply

ka1954 Apr. 9 at 1:39 PM

$NERV stop selling u idiots !!! if nobody sells this can rally

0 · Reply

NVDAMillionaire Mar. 26 at 10:58 AM

0 · Reply

NEWLONEWOLF09 Mar. 7 at 8:18 PM

$NERV okay this is dead. so many R/S and I am 95% down.

1 · Reply

ManfredMustermann Mar. 4 at 3:15 PM

$NERV when delisting?

0 · Reply

JarvisFlow Feb. 26 at 12:33 PM

HC Wainwright & Co. has adjusted their stance on Minerva Neurosciences ($NERV), setting the rating to Neutral with a target price of 5.

0 · Reply

Dardpro Feb. 26 at 12:13 PM

$NERV dead?

0 · Reply

ka1954 Feb. 6 at 10:42 PM

$NERV it has gone beteween 1.50 to 15 in last 3-4 years, that's the range. i think this year it could go back to $10+

0 · Reply

kshonstocks Feb. 5 at 6:50 PM

$NERV Total Cash Per Share (mrq) 3.79 https://finance.yahoo.com/quote/NERV/key-statistics/ had a yuge block last week

0 · Reply

Tumble51 Jan. 31 at 11:46 AM

$CADL tell that to the chartist at $NERV Stating $21 was next on Friday Oct 12 2022 It opened at $3 Monday morning !!! A chart guru !!! I got out at 13.25 Friday AM !!! Draw whatever lines you want, you don’t sit in the board room or the office of the CEO !!!

1 · Reply

Tradelyfe Jan. 30 at 1:42 PM

$NERV

1 · Reply

Tradelyfe Jan. 29 at 10:10 PM

$NERV looks sexy for an explosion

0 · Reply

reversalpicks Jan. 29 at 5:42 PM

$NERV potential to go up

0 · Reply

PenkeTrading Jan. 29 at 1:44 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Minerva Neurosciences Inc. Is that bullish or bearish? $NERV #RsiOverbought #NASDAQ

0 · Reply

Market Cap	11.54M
Revenue (ttm)	0.00
Net Income (ttm)	1.44M
EPS (ttm)	N/A
PE Ratio	2.11
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,200
Avg Vol	9,718
Day's Range	N/A - N/A
Shares Out	6.99M
Stochastic %K	27%
Beta	-0.34
Analysts	Hold
Price Target	$5.00